KemPharm, Inc. (NASDAQ:KMPH) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

KemPharm, Inc. (NASDAQ:KMPH) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security
Holders.

On May 23, 2017, KemPharm, Inc. (the
Company) held its 2017 Annual Meeting
of Stockholders (the 2017 Annual
Meeting), for the following purposes:

to elect two nominees for director, each to serve until the
2020 Annual Meeting of Stockholders and until his successor
has been elected and qualified or until his earlier death,
resignation or removal; and

to ratify the selection by the Audit Committee of the Board
of Directors ofRSM USLLP as the independent registered
public accounting firm of the Company for its fiscal year
ending December 31, 2017.

Of the 14,646,982 shares outstanding as of the record date,
12,479,509 shares, or 85.20%, were present or represented by
proxy at the 2017 Annual Meeting. At the 2017 Annual Meeting,
each ofRichard W. PascoeandDavid S. Tierneywas re-elected as a
director of the Company. The stockholders of the Company ratified
the appointment ofRSM USLLP as the Companys independent
registered public accounting firm for the Companys fiscal year
ending December 31, 2017. The final voting results on each of the
matters submitted to a vote of stockholders at the 2017 Annual
Meeting were as follows:

1.

Election of Directors

For

Withheld

Broker Non-Votes

Richard W. Pascoe

5,543,198

2,939,776

3,996,535

David S. Tierney

5,384,498

3,098,476

3,996,535

For

Against

Abstentions

Broker Non-Votes

2.

Ratification ofRSM USLLP as independent registered public
accounting firm for the Companys fiscal year ending
December 31, 2017

12,356,688

98,493

24,328


About KemPharm, Inc. (NASDAQ:KMPH)

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company’s products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.

KemPharm, Inc. (NASDAQ:KMPH) Recent Trading Information

KemPharm, Inc. (NASDAQ:KMPH) closed its last trading session down -0.10 at 3.95 with 12,164 shares trading hands.